Saxagliptin Impurity 15 manufacturers
- Saxagliptin Impurity 15
-
- $0.00 / 25kg
-
2025-12-01
- CAS:1496712-39-0
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
|
| | Saxagliptin Impurity 15 Basic information |
| Product Name: | Saxagliptin Impurity 15 | | Synonyms: | Saxagliptin Impurity 15 HCl;2-Azabicyclo[3.1.0]hexane-3-carboxamide, 2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-;(1S,3S,5S)-2-((S)-2-amino-2-((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide;Saxagliptin Impurity 19(BMS-554083);Saxagliptin Amide Impurity;Saxagliptin Amide ImpurityQ: What is
Saxagliptin Amide Impurity Q: What is the CAS Number of
Saxagliptin Amide Impurity Q: What is the storage condition of
Saxagliptin Amide Impurity Q: What are the applications of
Saxagliptin Amide Impurity;SaxagliptinImpurity15;Saxagliptin Hydrochloride(Dihydrate) Amide Impurity | | CAS: | 1496712-39-0 | | MF: | C18H27N3O3 | | MW: | 333.43 | | EINECS: | | | Product Categories: | | | Mol File: | 1496712-39-0.mol |  |
| | Saxagliptin Impurity 15 Chemical Properties |
| Boiling point | 603.4±40.0 °C(Predicted) | | density | 1.437±0.06 g/cm3(Predicted) | | pka | 15.12±0.40(Predicted) |
| | Saxagliptin Impurity 15 Usage And Synthesis |
| Uses | 3-Descarbonitrile 3-Acetamido Saxagliptin is a Saxagliptin (S143500) impurity, a potent and selective reversible inhibitor of dipeptidyl peptidase-4, which is being developed for the treatment of type 2 diabetes. It is absorbed rapidly after oral administration and has a pharmacokinetic profile compatible with once daily dosing. |
| | Saxagliptin Impurity 15 Preparation Products And Raw materials |
|
|
Tag:Saxagliptin Impurity 15(1496712-39-0)
Related Product Information
|
|
Saxagliptin
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2R)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1R,3R,5R)-
1H-Pyrrole-1-carboxylic acid, 2-(aMinocarbonyl)-2,3-dihydro-, 1,1-diMethylethyl ester, (2S)-
(1R,3R,5R)-2-Azabicyclo[3.1.0]hexane-3-carboxamide 2,2,2-trifluoroacetate
(1S,3S,5S)-2-(TERT-BUTOXYCARBONYL)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBOXYLIC ACID
3-Hydroxy-1-AdaMantane Carboxylic Acid
Saxagliptin Impurity 16
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1R,3S,5R)-
Tricyclo[3.3.1.13,7]decane-1-acetic acid, α-[[(1,1-diMethylethoxy)carbonyl]aMino]-3,5-dihydroxy-, (αS)-
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2R)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3R,5S)-
Saxagliptin iMpurity
(1R,3S,5R)-2-AZABICYCLO[3.1.0]HEXANE-3-CARBOXAMIDE 2,2,2-TRIFLUOROACETIC ACID
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2R)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-
Saxagliptin Impurity 34
Hydroxy Saxagliptin
2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-aMino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3R,5S)-
3H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazin-3-one, 6-aMino-1,1a,4,6a,7,7a-hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)-
1H-Cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-3,6-dione, hexahydro-4-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-, (1aS,4S,6aR,7aS)-
|